Pronóstico del mercado de adyuvantes de vacunas humanas de Asia Pacífico hasta 2030 – Análisis regional – por tipo (adyuvante en partículas, adyuvante en emulsión, adyuvante combinado y otros), aplicación (influenza, hepatitis, virus del papiloma humano (VPH) y otros) y usuario final ( Empresas Farmacéuticas y Biotecnológicas, CMOs y CROs, y Otros)

BMIRE00030361 | Pages: 113 | Pharmaceuticals | Jul 2024 | Type: Regional | Status: Published
El mercado de adyuvantes de vacunas humanas de Asia Pacífico se valoró en 330,19 millones de dólares en 2022 y se espera que alcance los 1.008,52 millones de dólares en 2030; se estima que registrará una tasa compuesta anual del 15,0% entre 2022 y 2030.

La creciente industria farmacéutica impulsa el mercado de adyuvantes de vacunas humanas de Asia Pacífico

Se espera que la industria farmacéutica en expansión influya positivamente en la demanda de adyuvantes ya que pueden mejorar la eficacia y seguridad de las vacunas. El creciente interés de la industria farmacéutica en las enfermedades infecciosas, el cáncer y los trastornos autoinmunes proporciona una plataforma para desarrollar vacunas y adyuvantes personalizados dirigidos a estas áreas de enfermedades específicas. Esto ofrece una oportunidad para que los fabricantes de adyuvantes desarrollen adyuvantes especializados para mejorar la respuesta inmune a las vacunas para estas enfermedades. Según EFPIA, las industrias farmacéuticas brasileña, china e india crecieron un 11,7%, un 6,7% y un 11,8% durante el período 2016-2021, respectivamente, en comparación con los cinco principales mercados de la Unión Europea y el mercado estadounidense, que registró un crecimiento promedio del mercado del 5,8% y 5,6%, respectivamente. Además, según la India Brand Equity Foundation (IBEF), la India es un actor importante y en ascenso en la industria farmacéutica mundial. El país es el mayor comerciante de medicamentos genéricos del mundo y representa casi el 20% del suministro mundial en volumen. Suministra aproximadamente el 50% de la demanda mundial de vacunación. La industria farmacéutica nacional incluye una red de 3.000 empresas farmacéuticas y ~10.500 unidades de fabricación. Según cifras oficiales del gobierno indio, el sector farmacéutico de la India está valorado en casi 50 mil millones de dólares, de los cuales más de 25 mil millones de dólares provienen de las exportaciones. India representa aproximadamente el 20% de las exportaciones mundiales de medicamentos genéricos. Además, Japón es uno de los mercados farmacéuticos más grandes del mundo. Según las Estadísticas Anuales de Producción Farmacéutica del Ministerio de Salud, Trabajo y Bienestar Social (MHLW), el mercado japonés de productos farmacéuticos con y sin receta en 2020 ascendió a 107 mil millones de dólares. A medida que la industria continúa evolucionando e innovando, existe una demanda creciente de adyuvantes que puedan respaldar el desarrollo de vacunas personalizadas, lo que impulsa un crecimiento y una inversión significativos en el mercado de adyuvantes de vacunas humanas de Asia Pacífico. Por lo tanto, la creciente industria farmacéutica en todo el mundo probablemente creará lucrativas oportunidades de crecimiento para el mercado de adyuvantes de vacunas humanas de Asia Pacífico en los próximos años.

Descripción general del mercado de adyuvantes de vacunas humanas de Asia Pacífico

China ha invertido mucho en sus industrias farmacéutica y de atención médica, con el objetivo de reforzar las capacidades nacionales de producción, investigación y desarrollo. Este enfoque estratégico ha posicionado al país como un actor clave en el mercado de adyuvantes de vacunas humanas de Asia Pacífico. Además, China se encuentra entre los países más densamente poblados del mundo; la población actual es ~1,41 mil millones. Según el último estudio sobre la Carga Global de Enfermedades (GBD) publicado en octubre de 2020, la población del país es propensa a diversas enfermedades infecciosas, crónicas y agudas.

Se espera que un aumento en la prevalencia de enfermedades infecciosas impulse la demanda de vacunas. Según un informe del Centro de Información ICO/IARC sobre el VPH y el Cáncer en 2023, China tiene una población de 582,4 millones de mujeres de 15 años o más que corren riesgo de desarrollar cáncer de cuello uterino relacionado con el VPH. Se estima que alrededor del 3,8% de las mujeres de la población general de China albergan infección cervical por VPH-16/18 en un momento dado, y el 69,1% de los cánceres de cuello uterino invasivos se atribuyen a los VPH 16 o 18. Por lo tanto, el creciente número de pacientes y También se espera que la creciente demanda de vacunas para el tratamiento impulse el crecimiento del mercado de adyuvantes de vacunas humanas de Asia Pacífico.

Ingresos del mercado de adyuvantes de vacunas humanas de Asia Pacífico y pronóstico hasta 2030 (millones de dólares estadounidenses)

Segmentación del mercado de adyuvantes de vacunas humanas de Asia Pacífico

Se clasifica el mercado de adyuvantes de vacunas humanas de Asia Pacífico por tipo, aplicación, usuario final y país.

Según el tipo, el mercado de adyuvantes de vacunas humanas de Asia Pacífico está segmentado como adyuvante particulado, adyuvante en emulsión, adyuvante combinado y otros. El segmento de adyuvantes de partículas tuvo la mayor cuota de mercado en 2022.

En términos de aplicación, el mercado de adyuvantes de vacunas humanas de Asia Pacífico se clasifica en influenza, hepatitis, virus del papiloma humano (VPH) y otros. El segmento de influenza tuvo la mayor participación de mercado en 2022.

Por usuario final, el mercado de adyuvantes de vacunas humanas de Asia Pacífico está segmentado en empresas farmacéuticas y de biotecnología, CMO y CRO, y otros. El segmento de empresas farmacéuticas y biotecnológicas tuvo la mayor cuota de mercado en 2022.

Por país, el mercado de adyuvantes de vacunas humanas de Asia Pacífico está segmentado en Japón, China, India, Australia, Corea del Sur y el resto de Asia Pacífico. . China dominó la cuota de mercado de adyuvantes de vacunas humanas de Asia Pacífico en 2022.

Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA y SPI Pharma Inc es una de las empresas líderes que operan en el mercado de adyuvantes de vacunas humanas de Asia Pacífico.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics

4.2 Market Drivers

4.2.1 Rising Prevalence of Chronic Diseases

4.2.2 Growing Focus on Immunization Programs

4.3 Market Restraints

4.3.1 Manufacturing Complexities and Regulatory Challenges

4.4 Market Opportunities

4.4.1 Growing Pharmaceutical Industry

4.5 Future Trends

4.5.1 Rising Trend of Personalized Vaccines

4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis

5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030

5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis

6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant

6.1.1 Overview

6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.2 Emulsion Adjuvant

6.2.1 Overview

6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.3 Combination Adjuvant

6.3.1 Overview

6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Others

6.4.1 Overview

6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza

7.1.1 Overview

7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.2 Hepatitis

7.2.1 Overview

7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Human papilloma virus (HPV)

7.3.1 Overview

7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Others

7.4.1 Overview

7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies

8.1.1 Overview

8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8.2 CMOs and CROs

8.2.1 Overview

8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis

9.1 Asia Pacific

9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)

9.1.1.1 China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.2 Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.3 India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.4 Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.5 South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Dynavax Technologies Corp

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 CSL Ltd

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Seppic SA

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 SPI Pharma Inc

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Hawaii Biotech Inc

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 Croda International Plc

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 Novavax Inc

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Phibro Animal Health Corp

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms

List of Tables

Table 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation

Table 2. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Table 3. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 4. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 5. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User

Table 6. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 7. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 8. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 9. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 10. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 11. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 12. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 13. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 14. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 15. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 16. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 17. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 18. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 19. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 20. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 21. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 22. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 23. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market

Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List of Figures

Figure 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030

Figure 4. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)

Figure 5. Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 6. Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)

Figure 10. Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Human Papilloma Virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)

Figure 15. Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)

Figure 19. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 20. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 21. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 22. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 23. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 24. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 25. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

1. Croda International Plc 
2. CSL Ltd 
3. Dynavax Technologies Corp 
4. Hawaii Biotech Inc 
5. Novartis AG 
6. Novavax Inc 
7. Phibro Animal Health Corp 
8. Seppic SA 
9. SPI Pharma Inc 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific human vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific human vaccine adjuvants market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440